Trial Profile
Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis Disease During 6 Months by Combinatorial Analysis of Serum Biomarkers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2022
Price :
$35
*
At a glance
- Drugs Etanercept (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms PRESA
- 01 Jun 2018 Status changed from recruiting to completed.
- 03 Feb 2017 New trial record